Videos

Survivor and pharmacist Kelly Gable, PharmD, BCPP, FAAPP, explains the overlooked challenges shaping patients’ day-to-day lives.

Experts detail the workflows and decisions behind launching complex bispecific therapies.

Multicenter data suggests dexamethasone may safely replace tocilizumab for low-grade CRS.

Oncology pharmacists explore how GLP-1 agents intersect with cancer treatments, overlapping toxicities, and shared decision-making.

Joseph Saseen, PharmD, explains the 2026 dyslipidemia guidelines' push for universal lipoprotein A screening, clarifies when apolipoprotein B testing adds value, and outlines how new FDA-approved therapies fit into the updated lipid-lowering treatment algorithm.

Experts discuss real-world BTCE challenges, toxicity monitoring, and evolving pharmacy practice.

Practical insights for navigating rare, high-stakes toxicities.

Expert insights on toxicity management, resistance mechanisms, and frontline integration of Bruton tyrosine kinase inhibitors in MCL.

In this final portion of the conversation, Matthew Arango, PharmD, reflects on the core principles pharmacists should keep front-of-mind when managing HER2-positive GEA. He shares perspectives on how the pharmacist’s role is poised to expand as new HER2-targeted therapies, biomarkers, and clinical data reshape the treatment landscape.

The panelists examined how the experience of vaccine mandates during COVID-19 fostered a lasting sense of distrust and resistance, with misinformation exploiting fear of making the wrong choice for oneself or one's child.

In this segment, Matthew Arango, PharmD, highlights the key moments when pharmacists add the most value within a multidisciplinary GEA care team—from initial treatment planning to ongoing patient support. He discusses how pharmacists streamline prior authorization for HER2-targeted therapies by ensuring complete, timely documentation and leveraging strategies that minimize delays.

The pharmacists examined the intersection of RSV prevention and antimicrobial stewardship, sparked by data showing that RSV drives more antibiotic prescribing than any other viral infection in children.

New data, emerging targets, and evolving ADC use are reshaping second-line decisions.

Matthew Warrick, PharmD, BCPS, BCOP, discusses mechanisms, safety nuances, and practical considerations shaping bispecific antibody use in lymphoma care.

A panel of neurology pharmacy specialists discusses the expanding clinical role of pharmacists in multiple sclerosis care.

Key risks, overlooked toxicities, and real-world monitoring strategies for bispecific T-cell engagers.

Oncology pharmacist Emma Jones, PharmD, BCOP, outlines how clinicians can recognize and manage these complex cases.

A dual-center retrospective study compares 2 fludarabine washout strategies to assess their impact on neutrophil engraftment, infections, growth factor use, and hospital length of stay.

Craig Beavers urges pharmacists to engage with obstructive hypertrophic cardiomyopathy (oHCM) management and explains how the alignment between mavacamten's clinical trial data and real-world outcomes validates its role as a safe, effective, and sustainable long-term therapy.

Disha Patel, PharmD, discusses current data on G-CSF use during HiDAC consolidation for AML, addressing relapse concerns, infection risk, clinical decision-making, and why practice patterns remain divided across institutions.

The panelists examined the 5-year follow-up data from the NATALEE trial, which evaluated the addition of ribociclib to a nonsteroidal aromatase inhibitor in patients with early breast cancer. Faculty examined how the patient population, study design, and clinical endpoints in this trial differed from those used in the monarchE trial. The discussion highlighted important distinctions in eligibility criteria and outcome measures that may influence interpretation of results. Experts reviewed the key efficacy findings from the 5-year analysis and discuss the safety profile observed with ribociclib in the adjuvant setting. Particular attention was given to how these outcomes inform the role of CDK4/6 inhibition in early-stage disease. Faculty shared their perspectives on the most meaningful clinical takeaways from the updated data. Finally, the panel compared the findings from NATALEE with the long-term results from monarchE and discuss how these studies together may shape treatment strategies and decision-making in clinical practice.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Joseph Saseen, PharmD, breaks down how the new PREVENT ASCVD calculator improves on its predecessor and what the expanded LDL-C goal framework means for treatment decisions in pharmacy practice.

From bispecifics to real-world evidence, Amy Seung previews the science, community, and advocacy opportunities defining this year's meeting.

Deucravacitinib, a selective TYK2 inhibitor, demonstrates efficacy comparable to biologics while offering meaningful improvements in symptoms and quality of life for patients with psoriatic arthritis.

Craig Beavers discusses how mavacamten's established long-term safety data strengthen shared decision-making conversations, and outlines best practices for multidisciplinary collaboration when implementing cardiac myosin inhibitor therapy in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Emerging therapies, AI, and patient-centered approaches are reshaping cardiovascular pharmacy.

CDK4/6 inhibitor therapies must by tailored by comorbidities, interactions, cost, and coordinated labs with pharmacist expertise to support high-risk patients.

Craig Beavers explains how mavacamten's REMS program and its clearly defined echo-based monitoring protocols create a unique opportunity for pharmacists to take an active role in managing patients with obstructive hypertrophic cardiomyopathy (oHCM).